EP2124968A4 - Compositions and methods for the treatment of muscle wasting - Google Patents

Compositions and methods for the treatment of muscle wasting

Info

Publication number
EP2124968A4
EP2124968A4 EP06774377.3A EP06774377A EP2124968A4 EP 2124968 A4 EP2124968 A4 EP 2124968A4 EP 06774377 A EP06774377 A EP 06774377A EP 2124968 A4 EP2124968 A4 EP 2124968A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
muscle wasting
wasting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06774377.3A
Other languages
German (de)
French (fr)
Other versions
EP2124968A1 (en
Inventor
Roderic M K Dale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lakewood-Amedex Inc
Original Assignee
Lakewood-Amedex Inc
Lakewood Amedex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lakewood-Amedex Inc, Lakewood Amedex Inc filed Critical Lakewood-Amedex Inc
Publication of EP2124968A1 publication Critical patent/EP2124968A1/en
Publication of EP2124968A4 publication Critical patent/EP2124968A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP06774377.3A 2006-06-30 2006-06-30 Compositions and methods for the treatment of muscle wasting Withdrawn EP2124968A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/025657 WO2008005002A1 (en) 2006-06-30 2006-06-30 Compositions and methods for the treatment of muscle wasting

Publications (2)

Publication Number Publication Date
EP2124968A1 EP2124968A1 (en) 2009-12-02
EP2124968A4 true EP2124968A4 (en) 2013-10-23

Family

ID=37102772

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06774377.3A Withdrawn EP2124968A4 (en) 2006-06-30 2006-06-30 Compositions and methods for the treatment of muscle wasting

Country Status (4)

Country Link
EP (1) EP2124968A4 (en)
AU (1) AU2006345724B2 (en)
CA (1) CA2558160C (en)
WO (1) WO2008005002A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2500921T3 (en) 2003-04-29 2014-10-01 Sarepta Therapeutics, Inc. Compositions to enhance the transport and antisense efficacy of nucleic acid analogs in cells
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
EP3554553B1 (en) 2016-12-19 2022-07-20 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
JP7510875B2 (en) * 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド Activin type IIB receptor mutants and pharmaceutical compositions containing the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006478A1 (en) * 2001-07-10 2003-01-23 Oligos Etc. Inc. Oligonucleotide-containing pharmacological compositions and their use
US20030129171A1 (en) * 1997-07-14 2003-07-10 Luc Grobet Double-muscling in mammals
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
CN1718194A (en) * 2005-06-24 2006-01-11 奥林格斯技术有限公司 Oligonucleotide medicine for treating myophagism
WO2006086667A2 (en) * 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129171A1 (en) * 1997-07-14 2003-07-10 Luc Grobet Double-muscling in mammals
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
WO2003006478A1 (en) * 2001-07-10 2003-01-23 Oligos Etc. Inc. Oligonucleotide-containing pharmacological compositions and their use
WO2006086667A2 (en) * 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
CN1718194A (en) * 2005-06-24 2006-01-11 奥林格斯技术有限公司 Oligonucleotide medicine for treating myophagism

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ACOSTA J ET AL: "Myostatin gene silenced by RNAi show a zebrafish giant phenotype", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 119, no. 4, 10 October 2005 (2005-10-10), pages 324 - 331, XP027663478, ISSN: 0168-1656, [retrieved on 20051010] *
ALEX CLOP ET AL: "A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep", NATURE GENETICS, vol. 38, no. 7, 4 June 2006 (2006-06-04), pages 813 - 818, XP055078053, ISSN: 1061-4036, DOI: 10.1038/ng1810 *
ALEX CLOP: "Supplementary Figure 5", NATURE GENETICS, 4 June 2006 (2006-06-04), pages 1 - 3, XP055078055, Retrieved from the Internet <URL:http://www.nature.com/ng/journal/v38/n7/extref/ng1810-S5.pdf> [retrieved on 20130906] *
DUMONCEAUX ET AL: "Improvement of Muscle Mass Using shRNA Targeting Myostatin or Activin Receptor IIb", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 13, 1 January 2006 (2006-01-01), pages S14, XP005675138, ISSN: 1525-0016 *
PANTOPOULOS K ET AL: "The role of the 5' untranslated region of eukaryotic messenger RNAs in translation and its investigation using antisense technologies", PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, ACADEMIC PRESS, US, vol. 48, 1 January 1994 (1994-01-01), pages 181 - 238, XP009172334, ISSN: 0079-6603 *
See also references of WO2008005002A1 *
THOMAS R. MAGEE ET AL: "Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass", THE JOURNAL OF GENE MEDICINE, vol. 8, no. 9, 29 June 2006 (2006-06-29), pages 1171 - 1181, XP055078809, ISSN: 1099-498X, DOI: 10.1002/jgm.946 *
ZADOR E ET AL: "Antisense inhibition of myoD expression in regenerating rat soleus muscle is followed by an increase in the mRNA levels of myoD, myf-5 and myogenin and by a retarded regeneration", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1590, no. 1-3, 12 June 2002 (2002-06-12), pages 52 - 63, XP004362110, ISSN: 0167-4889, DOI: 10.1016/S0167-4889(02)00198-2 *

Also Published As

Publication number Publication date
CA2558160A1 (en) 2007-12-30
AU2006345724A1 (en) 2008-01-10
WO2008005002A1 (en) 2008-01-10
AU2006345724B2 (en) 2013-11-21
CA2558160C (en) 2017-01-03
EP2124968A1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
IL196465A0 (en) Compositions and methods for the treatment of mucositis
HK1134679A1 (en) Compositions and methods for the treatment of infections
EP2361089A4 (en) Compositions and methods for the treatment of altered -synuclein function
GB0700919D0 (en) Degradable compositions, apparatus comprising same, and methods of use
IL197804A0 (en) Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
IL198723A0 (en) Methods and compositions for therapeutic treatment
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
EP2049151A4 (en) Methods and compositions for the treatment of cancer
GB0718446D0 (en) Compositions and methods for the treatment of infection
EP2124968A4 (en) Compositions and methods for the treatment of muscle wasting
EP1996218A4 (en) Methods and compositions for the treatment of gastrointestinal disorders
EP2217238A4 (en) Methods and compositions for the treatment of proteinuric diseases
GB0909297D0 (en) Composition for the treatment of skin conditions
IL187405A0 (en) Methods and compositions for the treatment of pain
GB0718918D0 (en) Compositions and methods for treating skin conditions
EP2096927A4 (en) Therapeutic compositions and methods of treatment with capsianoside-type compounds
EP2142566A4 (en) Methods and compositions for the treatment of proliferative diseases
EP2285398A4 (en) Methods and compositions for the treatment of obesity
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
GB0504657D0 (en) Compositions and methods of treatment
EP2094279A4 (en) Methods and compositions for treating influenza
ZA200710476B (en) Methods and compositions for the treatment of pain
GB2441581B (en) Compositions and methods for the treatment of muscle wasting

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090513

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LAKEWOOD-AMEDEX, INC

A4 Supplementary search report drawn up and despatched

Effective date: 20130920

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20130916BHEP

Ipc: A61K 31/70 20060101AFI20130916BHEP

Ipc: C12N 5/00 20060101ALI20130916BHEP

Ipc: C07H 21/02 20060101ALI20130916BHEP

Ipc: C12Q 1/68 20060101ALI20130916BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140423